Prosecution Insights
Last updated: November 15, 2026
Application No. 18/711,923

TRITIRACHIUM ALBUM PROTEINASE K MUTANT AND ITS ZYMOGEN, EXPRESSION PLASMID, RECOMBINANT PICHIA PASTORIS STRAIN AND METHOD OF PRODUCING THE MATURE FORM OF PROTEINASE K MUTANT

Non-Final OA §102§112
Filed
May 21, 2024
Priority
Nov 26, 2021 — PL P.439656 +1 more
Examiner
DICKENS, AMELIA NICOLE
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BLIRT S.A.
OA Round
1 (Non-Final)
48%
Grant Probability
Moderate
1-2
OA Rounds
70%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allowance Rate
61 granted / 128 resolved
-12.3% vs TC avg
Strong +22% interview lift
Without
With
+22.5%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
59 currently pending
Career history
184
Total Applications
across all art units

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group 1 (a mutant of the T. album proteinase K zymogen, claims 15-16) in the reply filed on 22 Sep 2026 is acknowledged. Claims 17-32 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 22 Sep 2026. Claim Status The amended claim set filed 22 Sep 2026 is acknowledged. Claims 15-32 are currently pending. Of those, claims 18, 26, and 28 are currently amended and no claims are new. Claims 17-32 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 22 Sep 2026. Claims 1-14 are cancelled. Claims 15-16 will be examined on the merits herein. References to the Specification The instant specification does not include paragraph numbers. To avoid ambiguity if future amendments to the specification change the page and line numbers where information is located, in this action references to the specification will use paragraph numbers from the Pre-Grant Publication US-20250019683-A1 (PTO-892). Priority This application claims priority to foreign priority document PLP.439656 (filed 26 Nov 2021) and is a 371 of PCT/PL2022/050084 (filed 25 Nov 2022). Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. However, support for the claimed subject matter in the foreign priority document cannot be assessed because an English translation has not been filed. So for the sake of searching the art, the effective filing date used is 25 Nov 2022 for all claims. The Office is not requiring that the foreign priority document be translated, but applicant cannot rely upon the earlier date from the certified copy of the foreign priority application to overcome an art rejection because a translation of said application has not been made of record in accordance with 37 CFR 1.55. When an English language translation of a non-English language foreign application is required, the translation must be that of the certified copy (of the foreign application as filed) submitted together with a statement that the translation of the certified copy is accurate. See MPEP §§ 215 and 216. Information Disclosure Statement The information disclosure statement (IDS) submitted on 21 May 2024 was filed in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. A signed copy of the statement is attached with this action. Specification The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. Specifically, [0056] has a hyperlink. Please remove the http:// prefix. Also, the disclosure is objected to because of the following informalities: Appropriate correction is required. At many locations, sequences in the specification are labeled “sequence” or “sequence No.”, rather than “SEQ ID NO:” as in the claims and sequence listing. The same reference style should be used throughout the application to make clear that it is referring to the same sequences. The preferred sequence reference is “SEQ ID NO:”. At [0060], the specification reads “…sequence 8 with the symbol pro-ProtK-G is joined in the correct reading frame (translational fusion) with the signal peptide on the pD912 vector with sequence 13 and the symbol ProtK-G SP”. However, SEQ ID NO: 8 is a nucleotide sequence and SEQ ID NO: 13 is an amino acid sequence. These two sequences cannot be joined in frame because they are different types of sequences. At [0061], the specification reads “…encoding the Tritirachium album recombinant proteinase K with sequence 16…”, but SEQ ID NO: 16 is a nucleotide, rather than an encoded protein sequence as described in this sentence. Also, earlier the paragraph stated that “…an expression plasmid with sequence 16 and the symbol pD912-ProtK-G is obtained…”. SEQ ID NO: 16 cannot both be an expression plasmid sequence and also the sequence of the encoded protein. At [0067], the specification reads “The expression strains of Pichia Pink/pPink_HC-ProtK-WT, Pichia pastoris/pD912-ProtK-G or Pichia pastoris/pD912-ProtK, obtained in Examples 5, 6 or 8, respectively, producing the recombinant (ProtK-G), native (ProtK-WT) or wild-type version of the mature proteinase K polypeptide, respectively”, but the order of “respectively” is incorrect and does not match the examples. The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. When considering amendments to the specification, please be mindful to not introduce new matter and to point out support for amendments. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 15-16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 15-16, the claims use the term “the Tritirachium album proteinase K zymogen”. MPEP 2173.05(a) requires that “The meaning of every term used in a claim should be apparent from the prior art or from the specification and drawings at the time the application is filed. Claim language may not be "ambiguous, vague, incoherent, opaque, or otherwise unclear in describing and defining the claimed invention." In re Packard, 751 F.3d 1307, 1311, 110 USPQ2d 1785, 1787 (Fed. Cir. 2014).” The term “zymogen” is not defined in the specification, so it is unclear what protein function (if any) is required of the claimed mutant. The specification states “The invention relates to a mutant of the Tritirachium album proteinase K zymogen containing a mutation that increases the efficiency of expression in yeast cells and facilitates the inactivation of mature proteinase K under stress at the C-terminus, the mutation being an additional Gly residue at the C-terminus. Preferably, the Tritirachium album proteinase K zymogen mutant of the invention has the sequence shown as sequence No. 9.” [0012] and also states “The invention also relates to a DNA sequence containing the coding sequence of a proteinase K zymogen mutant according to the invention as defined above or a fragment thereof. Preferably, it has sequence No. 8.” [0015]. SEQ ID NO: 8 encodes the protein sequence MAPAVEQRSEAAPLIEARGEMVANKYIVKFKEGSALSALDAAMEKISGKPDHVYKNVFSGFAATLDENMVRVLRAHPDVEYIEQDAVVTINAAQTNAPWGLARISSTSPGTSTYYYDESAGQGSCVYVIDTGIEASHPEFEGRAQMVKTYYYSSRDGNGHGTHCAGTVGSRTYGVAKKTQLFGVKVLDDNGSGQYSTIIAGMDFVASDKNNRNCPKGVVASLSLGGGYSSSVNSAAARLQSSGVMVAVAAGNNNADARNYSPASEPSVCTVGASDRYDRRSSFSNYGSVLDIFGPGTSILSTWIGGSTRSISGTSMATPHVAGLAAYLMTLGKTTAASACRYIADTANKGDLSNIPFGTVNLLAYNNYQAGRRAL, which is not the same as either SEQ ID NOs: 9 or 12. SEQ ID NO: 12 is only referenced three times in the specification, at par. [0046] as a description of the sequence listing, at the header of Example 4 (though not in the text of the example) and at [0064] as part of Example 7. None of these references define that SEQ ID NO: 12 is a zymogen or a mutant thereof. The term “Tritirachium album proteinase K zymogen” in claims is used by the claim to mean many different sequences that differ without explanation, and one of ordinary skill in the art would not be able to determine the meaning of the term and thus would not be able to determine the scope of function(s) that the protein must have (if any). The term is indefinite because the specification does not clearly define the term. In the interest of compact prosecution, this claim term will not be given weight because the claim is drawn to “a mutant” rather than “a zymogen”. The wording of the claim does not exclude the presence of other mutations within the sequence, including sequences where all positions of the wildtype sequence are mutated. As a consequence, the claim 15 will be examined so any amino acid sequence where a Gly residue is added at the C-terminus of the protein sequence falls within the scope of the claim. Regarding claim 15, claim 15 recites “an additional Gly residue at the C-terminus.” The term “additional” is a relative term which renders the claim indefinite. The term “additional” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention, because it is not clear what the Gly is in addition to. This description of the mutation is indefinite without a reference to compare to in order to determine whether or not an additional Gly is present at the C-terminus. In the interest of compact prosecution, the claim 15 will be examined so any amino acid sequence where a Gly residue is added at the C-terminus of the protein sequence falls within the scope of the claim. Dependent claim 16 is not included in this grounds of rejection because claim 16 requires a specific protein sequence be present. Regarding claim 16, the claim recites “the mutant possesses a sequence presented as SEQ ID NO. 12.” One of ordinary skill in the art would not be able to determine whether “possesses” should be interpreted as “comprising” or “consisting of”, and so claim scope is ambiguous. In the interest of compact prosecution, claim 16 will be examined as comprising SEQ ID NO: 12. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim 15 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Madison et al. (US 20090123452 A1; hereafter Madison; PTO-892). Madison teaches proteases can be fused to a non-protease polypeptide or tag by a flexible linker or spacer, and tags can include a histidine or GST tag [0380]. The linker can be fused to the C-terminus of the protease polypeptide [0380]. Specifically, Madison teaches an AT3 fusion protein, containing AT3 fused to a C-terminal 6*His tag using a four amino acid GGGS linker, which has the amino acid sequence of SEQ ID NO: 614 [0660], so the mutation comprises an additional Gly residue at the C-terminus and also comprises other additions at the C-terminus for remaining GGS in the linker, the 6*His tag, and mutations in the protein sequence itself. Madison SEQ ID NO: 614 is mutated relative to SEQ ID NO: 12 as shown in the alignment below. Alignment of SEQ ID NO: 12 and Madison SEQ ID NO: 614 (next page). PNG media_image1.png 1510 682 media_image1.png Greyscale Pertinent Prior Art The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Hildebrandt et al. (PL 213045 B1; made of record with IDS filed 21 May 2024) teaches proteinase K from Tritirachium album (pg. 2 par. 1 of “Patent Description”). Hildebrandt teaches that a His-tag or GST-tag would be a domain to facilitate purification, and that these tags could be introduced at the C-terminus of the mature proteinase K polypeptide to allow easier purification (pg. 3 par. 1). Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMELIA N DICKENS whose telephone number is (571)272-0381. The examiner can normally be reached M-F 8:30-4:30 (EDT/EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571) 270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. AMELIA N DICKENS Examiner Art Unit 1645 /AMELIA NICOLE DICKENS/Examiner, Art Unit 1645
Read full office action

Prosecution Timeline

May 21, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781182
BACILLUS SUBTILIS FNFH_BS08 AND USE THEREOF
3y 0m to grant Granted Nov 03, 2026
Patent 12751984
COMPOSITION CONTAINING A YEAST FOR PREVENTING SIMPLE AND/OR RECURRING CYSTITIS
4y 10m to grant Granted Oct 06, 2026
Patent 12748112
NEW SEROLOGICAL MARKER FOR THE LATENT FORM OF TOXOPLASMOSIS
4y 4m to grant Granted Sep 29, 2026
Patent 12740583
SYNERGISTIC BLENDS OF PROBIOTICS EXPRESSING IMPROVED BENEFICIAL ACTIVITY FOR HUMAN HOST FAVOURABLY INTERACTING WITH FOOD, PARTICULARLY BABY FOOD
4y 4m to grant Granted Sep 22, 2026
Patent 12724025
Method for Detecting Urinary Tract Infections and Sample Analysis Using Liquid Chromatography
5y 9m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
48%
Grant Probability
70%
With Interview (+22.5%)
Low
PTA Risk
Based on 128 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month